China’s First 2024 Biotech Acquisition by DCTY

Northeast’s DCTY Deal: A Landmark in China's Biotech Scene

In a groundbreaking move for China's biotechnology sector, the acquisition by Northeast's DCTY represents the nation's first domestic biotech takeover of 2024. This strategic decision positions the company at the forefront of advanced T-cell therapies, specifically targeting complex genetic mutations associated with cancer.